Blais MC, Bianco D, Goggs R et al. (2019) Consensus on the Rational Use of Antithrombics in Veterinary Critical Care (CURATIVE): Domain 3 - Defining antithrombotic protocols.Journal of Veterinary Emergency and Critical Care 29, 60–74

Sharp CR, deLaforcade AM, Koenigshof AM et al. (2019) Consensus on the Rational Use of Antithrombics in Veterinary Critical Care (CURATIVE): Domain 4 - Refining and monitoring antithrombotic therapies.Journal of Veterinary Emergency and Critical Care 29, 75–87

Helmond SE, Polzin DJ, Armstrong PJ et al. (2010) Treatment of immune-mediated hemolytic anemia with individually adjusted heparin dosing in dogs.Journal of  Veterinary Internal Medicine 24, 507–605

Lynch AM ,deLaforcade AM andSharp CR (2014)Clinical experience of anti-Xa monitoring in critically ill dogs receiving dalteparin. Journal of Veterinary Emergency and Critical Care 24 ,421–428

Smith CE ,Rozanski EA ,Freeman LM et al. (2004)Use of low molecular weight heparin in cats: 57 cases (1999–2003). Journal of the American Veterinary Medical Association 225 ,1237–1241

Babski DM, Brainard BM, Ralph AG et al. (2012) Sonoclot evaluation of single- and multiple-dose subcutaneous unfractionayed heparin therapy in healthy adult dogs.Journal of Veterinary Internal Medicine26, 631–638

Scott KC, Hansen BD and DeFrancesco TC (2009) Coagulation effects of low molecular weight heparin compared with heparin in dogs considered to be at risk for clinically significant venous thrombosis.Journal of Veterinary Emergency and Critical Care19, 74–80

Mischke R, Schmitt J, Wolken S et al. (2012) Pharmacokinetics of the low molecular weight heparin dalteparin in cats.Veterinary Journal192, 299–303